BiotechTube

Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liver Cirrhosis

Conditions

Liver Cirrhosis

Trial Timeline

Feb 15, 2024 → Dec 11, 2024

NCT ID
NCT06269484

About Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin

Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin is a phase 2 stage product being developed by AstraZeneca for Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06269484. Target conditions include Liver Cirrhosis.

What happened to similar drugs?

20 of 20 similar drugs in Liver Cirrhosis were approved

Approved (20) Terminated (3) Active (0)
✅Advagraf + Prograf + PrografAstellas PharmaApproved
✅Prograf + AdvagrafAstellas PharmaApproved
✅ADVAGRAF®Astellas PharmaApproved
✅Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
✅Advagraf + PrografAstellas PharmaApproved
✅ADVAGRAF®Astellas PharmaApproved
✅tacrolimus + mycophenolate mofetil + PrednisoneAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06269484Phase 2Completed

Competing Products

20 competing products in Liver Cirrhosis

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
29
GODEX + PlaceboCelltrionPhase 3
47
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
TacrolimusAstellas PharmaPre-clinical
26
ATG (Fresenius Biotech)Astellas PharmaPhase 2
27
Advagraf + Prograf + PrografAstellas PharmaApproved
43
Prograf + AdvagrafAstellas PharmaApproved
43
ADVAGRAF®Astellas PharmaApproved
43
Prograf + MR4Astellas PharmaPhase 3
40
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 3
40
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
40
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
40
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
43
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
40
FK778Astellas PharmaPhase 2
35
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
40
Advagraf + PrografAstellas PharmaApproved
39